Gibson Dunn Reps Accuray In $277M Radiotherapy Deal

Law360, New York (March 7, 2011, 7:25 PM EST) -- California radiation oncology company Accuray on Monday announced plans to buy TomoTherapy Inc. for $277 million, creating a new global cancer treatment provider expected to pull in annual revenue of more than $400 million.

Accuray, based in Sunnyvale, said it will acquire TomoTherapy Inc. for $4.80 per share in cash and stock. Accuray president and CEO Euan S. Thomson said the acquisition will create a company that will provide patients with treatments ranging from high-precision radiosurgery to image-guided, intensity-modulated radiation therapy.

“The combined company will also...
To view the full article, register now.